Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trialSalah‐Eddin Al‐Batran, Alexander Reichart, Nils Homann et al.|The Lancet|2019Cited by 2.6k
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trialSalah‐Eddin Al‐Batran, Andrea Tannapfel, Ralf‐Dieter Hofheinz et al.|The Lancet Oncology|2016Cited by 738
The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction – a phase III trial of the German AIO/CAO-V/CAOGISalah‐Eddin Al‐Batran, Stefan Paul Moenig, Thorsten Oliver Goetze et al.|BMC Cancer|2017Cited by 226
A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport’s syndromeOliver Groß, Markus Feldkoetter, Peter F. Hoyer et al.|Kidney International|2020Cited by 151